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Introduction
Patients with AIDS, organ transplants, cancer, diabetes, 
autoimmune disorders, biomedical-assist devices, or long-
term antibiotic therapy are at major risk of developing my-
cosis [1, 2]. Reports of invasive aspergillosis and candidiasis 
in immunocompromised patients have been increasing [3, 
4]. Candida spp. can affect almost all organ systems in the 
human body. The genome plasticity and high reproductive 
capacity constitute a serious risk to human health [5, 6].  Ni-
statine in one of the few topical drugs for the treatment of 
cutaneous mycosis caused by this pathogen [7]. Reports of 
resistance to antimycotic agents have been reported for sev-
eral years [8]. Thus, every year it is more difficult to predict 
clinical success /failure and duration of antimycotic therapy. 
The therapeutic options are quite limited and don’t provide 
expected results [9, 10]. The introduction of new drugs 
could help to manage this critical situation. 
The computer-aided study of novel 5-aryl-2thio-
1,3,4-oxadiazoles reported in vitro anti-tubercular activ-
ity of phenoxythiazolchloralum (MF-0010) (fig. 1) against 
Mycobacterium tuberculosis H37Rv [11]. Pharmacophore 
groups –NH-, =C=O, =N-N=, -Cl produce three-dimen-
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Abstract
Background: The therapeutic options in invasive candidiasis and aspergillosis are limited and don’t provide expected results. Introducing a new drug in 
the therapeutic practice can improve the quality of life of immunocompromised patients. The aim of this research is to study the antimycotic activity of 
new substance phenoxithiazolchloralum (MF-0010) on Aspergillus spp., Candida albicans, and Saccharomyces cerevisiae.
Material and methods: Phenoxythiazolchoralum has been kindly offered by the Institute of Chemistry. The standards were offered by Nicolae Testemitanu 
State University of Medicine and Pharmacy. Antifungal activity of the phenoxythiazolchloralum against Aspergillus spp. was evaluated by microdilution 
method. The successive double dilution method was used for determination of in vitro susceptibility against Candida albicans, and Saccharomyces cerevisiae.
Results: For the first time, it was studied in vitro susceptibility of MF-0010 against Aspergillus spp., Candida albicans, Saccharomyces cerevisiae. With at 
least 0.05 μM/ml difference of MF-0010 MIC value from standards, it can be considered quite more potent than ketoconazole and bifonazole against 
Aspergillus fumigatus, Aspergillus versicolor, Aspergillus ochramensis. The MIC/MCF ratios of MF-0010 are lower than nistatine ones with 0.08 μMol for 
both pathogens: Candida albicans, and Saccharomyces cerevisiae.
Conclusions: All analyzed pathogens were susceptible to MF-0010. According to experimental data on Aspergillus spp., the antimycotic activity of 
MF-0010 is quite better than the standards one. The MIC/MCF ratios showed in vitro significant susceptibility of MF-0010 against Candida albicans.
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Fig. 1.  The chemical structure of  
phenoxythiazolchloralum (MF-0010)
 Acute toxicity tests reveal that MF-0010 in mice after in-
traperitoneal injection and intragastric administration for 
a single dose suggests that compound has minimal toxicity, 
and can be placed in the toxicity class 5 according to TG 
423 Acute Toxic Class Method (OECD) [13]. Organoleptic 
characteristics, solubility, melting temperature and UV ab-
sorption spectra are described by O. Butescu [14]. It was 
observed that compound has poor solubility in polar sol-
vents (water, methanol, ethanol, acetonitrile, acetone) and 
low bioavailability that limits the use as antitubercular 
agent.  Following research of chemical structure showed 
that substance could have other biological activities. The 
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presence of the azole ring (pharmacophore group of azole 
antimycotic drug) suggests that the studied substance may 
have antimycotic activity.
The aim of this research is to study the antimycotic acti-




For evaluating of the antifungal activity of the phenoxy-
thiazolchloralum compound against Aspergillus spp. was 
used the microdilution method described by E. Stingaci et 
al. [15].
Candida albicans and Saccharomyces cerevisiae
For evaluating of the antifungal activity for Candida al-
bicans, and Saccharomyces cerevisiae was used the successive 
double dilution method. For this, at the initial stage, 1 mL of 
Sabouraud broth for test fungus was introduced into a series 
of 10 tubes. Subsequently, 1 mL of the analyzed compound 
was dropped into the first test tube.
Then, the obtained mixture was pipetted, after that 1 mL 
of it was transferred to the next tube, so the procedure was 
repeated until the tube No 10 of the series. Thus, the con-
centration of the initial preparation decreased 2-fold in each 
subsequent tube.
At the same time, 24 hour test fungi of  Candida albi-
cans and Saccharomyces cerevisiae were prepared. Initially, 
suspensions of test fungi were prepared with optical densi-
ties (D.O.) of 0.5 according to the McFarland index. Sub-
sequently, 1 mL of the obtained fungal suspension was 
dropped in a tube containing 9 mL of sterile distilled water. 
The content of the tube was mixed, after which 1 mL was 
transferred to the tube No 2 of the 5-tube series containing 
9 mL of sterile distilled water.
From the 5-th tube of the series was taken 0.1 mL of the 
fungal suspension, which represents the seeded dose and 
added to each tube with titrated preparation. Subsequently, 
the tubes with titrated preparation and the seeded doses of 
the microorganisms were put in the thermostat at 35°C for 
24 hours. On the second day, a preliminary analysis of the 
results was made. The last tube from the series in which no 
visible growth of microorganisms has been detected was 
considered to be the minimal inhibitory concentration 
(MIC) of the preparation.
For the estimation of the minimum fungicidal concen-
tration (MFC), the contents of the test tubes with MIC and 
with higher concentrations were seeded on Sabouraud agar 
from Petri dishes with the use of the bacteriological loop. 
The seeded dishes were kept in the thermostat at 35oC for 
24 hours. The concentration of preparation, which did not 
allow the growth of any colony of microorganisms, was con-




For the first time, it was studied in vitro susceptibility of 
MF-0010 against A. fumigatus, A. versicolor, A. ochramensis 
and A. niger. The MIC and MFC values of MF-0010 against 
Aspergillus spp. ranged from 0.23 μM/ml – 0.62 μM/ml 
(fig. 2) and 0.62 μM/ml –1.24 μM/ml (fig. 3), respectively. 
The highest values of MIC and MCF of MF-0010 are related 
to A. niger.  Thus, the use of MF-0010 against this pathogen 
is not appropriate. 
The MIC values of MF-0010 on A. fumigatus, A. versi-
color, A. ochramensis and A. niger are  0.23 μM/ml -0.31 μM/
ml, which are lower than MICs of standards: ketoconazole 
(0.28 μM/ml-0,38 μM/ml) and bifonazole (0.32 μM/ml-0.48 
μM/ml). With at least 0.05 μM/ml difference from stan-
dards, MF-0010 can be considered quite more potent than 
ketoconazole and bifonazole.
The MCF value of MF-0010 against A. fumigatus, A. ver-
sicolor, A. ochramensis and A. niger is  0.62 μM/ml, which is 
lower than MFC values of standards: ketoconazole – 0.94 
μM/ml (exception is A.ochramensis – 0.38 μM/ml) and bi-
fonazole – 0.64 μM/ml. With a 0.02 μM/ml difference from 
standards, MF-0010 has the same antimycotic activity as bi-
fonazole, and better one than ketoconazole.
Fig. 2.  The Minimum Inhibitory Concentration (MIC)  
of MF-0010, ketoconazole, bifonazole against A. fumigatus, A. versicolor, A. ochramensis and A. niger
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Candida albicans and Saccharomyces cerevisiae
For the first time, it was studied the in vitro inhibition 
potential of MF-0010 against Candida albicans, Saccharo-
myces cerevisiae (fig. 4). 
The MIC/MCF ratios of MF-0010 for inhibition of Can-
dida albicans, Saccharomyces cerevisiae are lower than ni-
statine ones with 0.08 μMol for both pathogens. Thus, we 
can conclude that MF-0010 is more potent active molecule 
than nistatine against Candida albicans. Further research is 
needed to create topical forms and confirm by clinical trial 
the pharmacological action, pharmacokinetic profile and 
safety of formulations with MF-0010.  Several types of topi-
cal medication including creams, ointments, and pastes can 
be designed.
Conclusions
In this study, we found that all analyzed pathogens were 
susceptible to MF-0010. According to the experimental data, 
the antimycotic activity of MF-0010 is quite better than the 
standard one.  The MIC and MCF values of MF-0010 show 
a good potency against Candida albicans, and new studies 
are warranted in order to design optimized formulations, 
to analyze in vivo the efficacy and quality assurance of for-
mulations.
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